Europe Non-Insulin Diabetes Therapies Market

Europe Non-Insulin Diabetes Therapies Market Size (2022 to 2027)

The size of the Europe Non-Insulin Diabetes Therapies market is predicted to be growing at a CAGR of 4.77% from 2022 to 2027. The size of the market is estimated to be USD 3.17 billion by 2027 from USD 2.51 billion in 2022.

The significant increase in diabetes patients, growing demand for combination therapy, and rapid advancements in diabetes treatment are fuelling the growth rate of the European non-insulin diabetes therapies market. On the other hand, the Growing geriatric population is more prone to various chronic diseases such as diabetes. The change in lifestyle and food habits is the cause of diabetes. Diabetes is becoming an increasingly common health condition, which can disable patients and potentially lead to fatal health complications. The other factors such as unhealthy diet and increasing levels of physical inactivity are led to diabetes. 

Diabetes could strike anybody at any age, although it is more frequent in people over 60. One in four adults over the age of 65 has diabetes. Diabetes is more likely to occur in people who are overweight, older, or have other diseases such as pancreatic problems or high blood pressure. Diabetes is the sixth greatest cause of mortality. 

The key market participants in this region are using strategies including partnerships, collaborations, and mergers to counter the competitive and fragmented character of the regional non-insulin treatments for the diabetes market. Players can use these strategies to develop their business regionally. However, the major companies are incorporating advanced technologies into their offerings. These technologies can anticipate, monitor, and adapt to their environment. These technical advancements offer manufacturers a competitive advantage over their competitors, allowing them to maintain a stronghold on the European non-insulin diabetic treatments market.

Diabetes is a prevalent condition, therefore making these medicines available to individuals of all socioeconomic groups is a major challenge. Also, the government initiatives about increasing people’s attention are not in huge numbers and thus restrict the growth of the market. Furthermore, many people in rural areas are still unaware of the benefits of these medicines, thus raising awareness is a problem.

This research report on the European non-insulin diabetes therapies market has been segmented and sub-segmented into the following categories:

By Drug Type:

• Sulphonylureas     
• Amylin Agonists    
• GLP-1 Agonists & Analogs
• Biguanides             
• Glinides & Meglinitides      
• Sodium-Glucose cotransporter 2 (SGLT2) Inhibitors
• Thiazolidinediones (or Glitazones or TZDs 
• Alpha-Glucosidase Inhibitors         
• Dipeptidyl Peptidase-4 (DPP4) Inhibitors

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the European market is projected to account significant share in the Non-Insulin Diabetes Therapies Market. The market growth is attributed to the proliferation of diabetes, and Increasing demand for combination therapy and rapid advancements in diabetes treatment are propelling the market growth. Countries such as Germany, UK, France, Spain, and Italy significantly contribute to the regional market growth.

In the regional market, Germany dominated the Non-insulin Diabetes therapies market and accounted for significant market revenue. The increasing number of people with type 2 diabetes, increasing demand for diabetes drugs, and rising healthcare spending are fuelling the market growth in Germany.  Recent analysis shows us, in Germany around 5 million people are facing diabetic problems. Because of the growth in the number of people facing diabetic problems, the growth in this market is expected to increase exponentially in the coming years.

Similarly, the UK is anticipated to witness a significant share in the coming future due to the technological advancements in the healthcare sector. The availability of advanced treatments solutions for diabetes is accelerating the market growth.

On the other hand, the countries such as Italy, France, and Spain are projected to have a moderate share in Non-Insulin Diabetes Therapies Market and contribute to the European regional market growth. Government initiatives and Favourable reimbursement policies are augmenting the market growth.

KEY MARKET PLAYERS:

Promising companies treating Diabetes in the market include Tobira (New Jersey), Eli Lilly and Sumitomo Dainippon Pharma (Japan), Novo Nordisk (Denmark), Takeda (Japan), Sanofi (China), Mannkind (California), Bristol-Myers Squibb (New York), AstraZeneca (U.K), Boehringer Ingelheim (Germany) and Bayer (Germany).